zanubrutinib-话题@MedSci - 梅斯（MedSci）

#zanubrutinib#

17篇内容 | 1640人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1348553, encodeId=ecf213485535e, content=<a href='/topic/show?id=b91f19002f0' target=_blank style='color:#2F92EE;'>#zanubrutinib#</a>, objectTitle=Lancet Oncol：Zanubrutinib vs 苯达莫司汀-利妥昔单抗治疗初治慢性淋巴细胞白血病和小淋巴细胞淋巴瘤, objectType=article, longId=731945, objectId=fdbde3194517, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fdbde3194517, replyNumber=0, likeNumber=112, createdTime=2022-07-11, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fdbde3194517, moduleTitle=Lancet Oncol：Zanubrutinib vs 苯达莫司汀-利妥昔单抗治疗初治慢性淋巴细胞白血病和小淋巴细胞淋巴瘤, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=fdbde3194517)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1348552, encodeId=e46613485520d, content=<a href='/topic/show?id=b91f19002f0' target=_blank style='color:#2F92EE;'>#zanubrutinib#</a>, objectTitle=Clin Cancer Res：采用新型BTK抑制剂Zanubrutinib治疗复发/难治性边缘区淋巴瘤, objectType=article, longId=221654, objectId=607c22165460, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=607c22165460, replyNumber=0, likeNumber=76, createdTime=2021-12-08, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=607c22165460, moduleTitle=Clin Cancer Res：采用新型BTK抑制剂Zanubrutinib治疗复发/难治性边缘区淋巴瘤, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=607c22165460)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1348551, encodeId=ea7d1348551cb, content=<a href='/topic/show?id=b91f19002f0' target=_blank style='color:#2F92EE;'>#zanubrutinib#</a>, objectTitle=Clin Cancer Res：BTK抑制剂Zanubrutinib治疗复发/难治性Waldenströms巨球蛋白血症(WM)的疗效, objectType=article, longId=214279, objectId=44752142e9a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=44752142e9a0, replyNumber=0, likeNumber=69, createdTime=2021-07-17, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=44752142e9a0, moduleTitle=Clin Cancer Res：BTK抑制剂Zanubrutinib治疗复发/难治性Waldenströms巨球蛋白血症(WM)的疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=44752142e9a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1348550, encodeId=51ad13485503e, content=<a href='/topic/show?id=b91f19002f0' target=_blank style='color:#2F92EE;'>#zanubrutinib#</a>, objectTitle=美国FDA接受BRUKINSA（Zanubrutinib）治疗Waldenström巨球蛋白血症的补充新药申请, objectType=article, longId=207300, objectId=047f20e30032, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=047f20e30032, replyNumber=0, likeNumber=75, createdTime=2021-02-20, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=047f20e30032, moduleTitle=美国FDA接受BRUKINSA（Zanubrutinib）治疗Waldenström巨球蛋白血症的补充新药申请, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=047f20e30032)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1348549, encodeId=076a1348549dc, content=<a href='/topic/show?id=b91f19002f0' target=_blank style='color:#2F92EE;'>#zanubrutinib#</a>, objectTitle=Clini Cancer Research：新型BTK抑制剂Zanubrutinib治疗复发性/难治性MCL, objectType=article, longId=197074, objectId=2ffd19e07469, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ffd19e07469, replyNumber=0, likeNumber=67, createdTime=2020-07-06, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ffd19e07469, moduleTitle=Clini Cancer Research：新型BTK抑制剂Zanubrutinib治疗复发性/难治性MCL, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=2ffd19e07469)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1348548, encodeId=3960134854896, content=<a href='/topic/show?id=b91f19002f0' target=_blank style='color:#2F92EE;'>#zanubrutinib#</a>, objectTitle=百济神州的BTK抑制剂zanubrutinib治疗淋巴瘤，获得了FDA的优先审查, objectType=article, longId=178216, objectId=e9211e8216cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e9211e8216cb, replyNumber=0, likeNumber=0, createdTime=2019-08-28, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e9211e8216cb, moduleTitle=百济神州的BTK抑制剂zanubrutinib治疗淋巴瘤，获得了FDA的优先审查, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e9211e8216cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1348547, encodeId=38b7134854ec9, content=<a href='/topic/show?id=b91f19002f0' target=_blank style='color:#2F92EE;'>#zanubrutinib#</a>, objectTitle=Blood：高选择性BTK抑制剂zanubrutinib用于CLL/SLL的活性和安全性, objectType=article, longId=176194, objectId=46cc1e6194e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46cc1e6194e7, replyNumber=0, likeNumber=77, createdTime=2019-07-27, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46cc1e6194e7, moduleTitle=Blood：高选择性BTK抑制剂zanubrutinib用于CLL/SLL的活性和安全性, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=46cc1e6194e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1348546, encodeId=6d97134854687, content=<a href='/topic/show?id=b91f19002f0' target=_blank style='color:#2F92EE;'>#zanubrutinib#</a>, objectTitle=百济神州宣布美国食品药品监督管理局（FDA）授予Zanubrutinib突破性疗法认定用于治疗套细胞淋巴瘤患者, objectType=article, longId=158141, objectId=4f381581410d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4f381581410d, replyNumber=0, likeNumber=80, createdTime=2019-01-17, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f381581410d, moduleTitle=百济神州宣布美国食品药品监督管理局（FDA）授予Zanubrutinib突破性疗法认定用于治疗套细胞淋巴瘤患者, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=4f381581410d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1348545, encodeId=f127134854534, content=<a href='/topic/show?id=b91f19002f0' target=_blank style='color:#2F92EE;'>#zanubrutinib#</a>, objectTitle=李志铭教授：疗效与安全性双赢--新型BTK抑制剂Zanubrutinib为B细胞淋巴瘤患者带来治疗新选择, objectType=article, longId=157138, objectId=55df15e138c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55df15e138c5, replyNumber=0, likeNumber=99, createdTime=2019-01-02, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55df15e138c5, moduleTitle=李志铭教授：疗效与安全性双赢--新型BTK抑制剂Zanubrutinib为B细胞淋巴瘤患者带来治疗新选择, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=55df15e138c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1348544, encodeId=cf9e13485441f, content=<a href='/topic/show?id=b91f19002f0' target=_blank style='color:#2F92EE;'>#zanubrutinib#</a>, objectTitle=邹德慧教授：Zanubrutinib在套细胞淋巴瘤（MCL）等多种B细胞淋巴瘤中应用前景广阔，成为我国自主研发药的重大里程碑, objectType=article, longId=156972, objectId=67fa1569e267, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=67fa1569e267, replyNumber=0, likeNumber=77, createdTime=2018-12-31, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=67fa1569e267, moduleTitle=邹德慧教授：Zanubrutinib在套细胞淋巴瘤（MCL）等多种B细胞淋巴瘤中应用前景广阔，成为我国自主研发药的重大里程碑, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=67fa1569e267)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1348543, encodeId=407c134854329, content=<a href='/topic/show?id=b91f19002f0' target=_blank style='color:#2F92EE;'>#zanubrutinib#</a>, objectTitle=Zanubrutinib治疗MCL全球多中心临床试验AU-003结果显示良好的有效性和安全性, objectType=article, longId=154866, objectId=91ab154866a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=91ab154866a4, replyNumber=0, likeNumber=99, createdTime=2018-12-02, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=91ab154866a4, moduleTitle=Zanubrutinib治疗MCL全球多中心临床试验AU-003结果显示良好的有效性和安全性, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=91ab154866a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1348542, encodeId=78cb13485422e, content=<a href='/topic/show?id=b91f19002f0' target=_blank style='color:#2F92EE;'>#zanubrutinib#</a>, objectTitle=新一代BTK抑制剂Zanubrutinib具有多重优势, objectType=article, longId=154851, objectId=cf8715485131, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf8715485131, replyNumber=0, likeNumber=128, createdTime=2018-12-02, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf8715485131, moduleTitle=新一代BTK抑制剂Zanubrutinib具有多重优势, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=cf8715485131)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1348541, encodeId=05711348541ef, content=<a href='/topic/show?id=b91f19002f0' target=_blank style='color:#2F92EE;'>#zanubrutinib#</a>, objectTitle=朱军教授：新一代BTK抑制剂Zanubrutinib具有多重优势, objectType=article, longId=154636, objectId=cc21154636ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cc21154636ff, replyNumber=0, likeNumber=128, createdTime=2018-12-01, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cc21154636ff, moduleTitle=朱军教授：新一代BTK抑制剂Zanubrutinib具有多重优势, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=cc21154636ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1348540, encodeId=091913485402a, content=<a href='/topic/show?id=b91f19002f0' target=_blank style='color:#2F92EE;'>#zanubrutinib#</a>, objectTitle=【2018CSH】赵维莅教授：新一代BTK抑制剂Zanubrutinib的应用体会及前景展望肿瘤资讯昨天, objectType=article, longId=152201, objectId=c131152201af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c131152201af, replyNumber=0, likeNumber=105, createdTime=2018-10-31, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c131152201af, moduleTitle=【2018CSH】赵维莅教授：新一代BTK抑制剂Zanubrutinib的应用体会及前景展望肿瘤资讯昨天, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c131152201af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1348539, encodeId=6bf41348539b7, content=<a href='/topic/show?id=b91f19002f0' target=_blank style='color:#2F92EE;'>#zanubrutinib#</a>, objectTitle=百济神州宣布NMPA接受zanubrutinib新药上市申请及关键性研究数据, objectType=article, longId=151867, objectId=382915186e3a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=382915186e3a, replyNumber=0, likeNumber=112, createdTime=2018-10-26, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=382915186e3a, moduleTitle=百济神州宣布NMPA接受zanubrutinib新药上市申请及关键性研究数据, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=382915186e3a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1348538, encodeId=bd2f134853801, content=<a href='/topic/show?id=b91f19002f0' target=_blank style='color:#2F92EE;'>#zanubrutinib#</a>, objectTitle=CSCO 2018 | 第二代BTK抑制剂Zanubrutinib，持久和特异的靶向亲和力带来更优的疗效和安全性, objectType=article, longId=149438, objectId=e16114943801, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e16114943801, replyNumber=0, likeNumber=107, createdTime=2018-09-25, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e16114943801, moduleTitle=CSCO 2018 | 第二代BTK抑制剂Zanubrutinib，持久和特异的靶向亲和力带来更优的疗效和安全性, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e16114943801)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1348537, encodeId=3cec134853ec3, content=<a href='/topic/show?id=b91f19002f0' target=_blank style='color:#2F92EE;'>#zanubrutinib#</a>, objectTitle=百济神州宣布中国药监局接受zanubrutinib用于治疗复发/难治性套细胞淋巴瘤的新药申请, objectType=article, longId=147531, objectId=c60e14e531c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c60e14e531c9, replyNumber=0, likeNumber=84, createdTime=2018-08-29, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c60e14e531c9, moduleTitle=百济神州宣布中国药监局接受zanubrutinib用于治疗复发/难治性套细胞淋巴瘤的新药申请, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c60e14e531c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

zanubrutinib

2020-05-29

bugit (审核中...)

前往app查看评论内容

#zanubrutinib#

Lancet Oncol：Zanubrutinib vs 苯达莫司汀-利妥昔单抗治疗初治慢性淋巴细胞白血病和小淋巴细胞淋巴瘤

2022-07-11

bugit (审核中...)

前往app查看评论内容

#zanubrutinib#

Clin Cancer Res：采用新型BTK抑制剂Zanubrutinib治疗复发/难治性边缘区淋巴瘤

2021-12-08

bugit (审核中...)

前往app查看评论内容

#zanubrutinib#

Clin Cancer Res：BTK抑制剂Zanubrutinib治疗复发/难治性Waldenströms巨球蛋白血症(WM)的疗效

2021-07-17

bugit (审核中...)

前往app查看评论内容

#zanubrutinib#

美国FDA接受BRUKINSA（Zanubrutinib）治疗Waldenström巨球蛋白血症的补充新药申请

2021-02-20

bugit (审核中...)

前往app查看评论内容

#zanubrutinib#

Clini Cancer Research：新型BTK抑制剂Zanubrutinib治疗复发性/难治性MCL

2020-07-06

bugit (审核中...)

前往app查看评论内容

#zanubrutinib#

百济神州的BTK抑制剂zanubrutinib治疗淋巴瘤，获得了FDA的优先审查

2019-08-28

bugit (审核中...)

前往app查看评论内容

#zanubrutinib#

Blood：高选择性BTK抑制剂zanubrutinib用于CLL/SLL的活性和安全性

2019-07-27

bugit (审核中...)

前往app查看评论内容

#zanubrutinib#

百济神州宣布美国食品药品监督管理局（FDA）授予Zanubrutinib突破性疗法认定用于治疗套细胞淋巴瘤患者

2019-01-17

bugit (审核中...)

前往app查看评论内容

#zanubrutinib#

李志铭教授：疗效与安全性双赢--新型BTK抑制剂Zanubrutinib为B细胞淋巴瘤患者带来治疗新选择

2019-01-02

bugit (审核中...)

前往app查看评论内容

#zanubrutinib#

邹德慧教授：Zanubrutinib在套细胞淋巴瘤（MCL）等多种B细胞淋巴瘤中应用前景广阔，成为我国自主研发药的重大里程碑

2018-12-31

bugit (审核中...)

前往app查看评论内容

#zanubrutinib#

Zanubrutinib治疗MCL全球多中心临床试验AU-003结果显示良好的有效性和安全性

2018-12-02

bugit (审核中...)

前往app查看评论内容

#zanubrutinib#

新一代BTK抑制剂Zanubrutinib具有多重优势

2018-12-02

bugit (审核中...)

前往app查看评论内容

#zanubrutinib#

朱军教授：新一代BTK抑制剂Zanubrutinib具有多重优势

2018-12-01

bugit (审核中...)

前往app查看评论内容

#zanubrutinib#

【2018CSH】赵维莅教授：新一代BTK抑制剂Zanubrutinib的应用体会及前景展望肿瘤资讯昨天

2018-10-31

bugit (审核中...)

前往app查看评论内容

#zanubrutinib#

百济神州宣布NMPA接受zanubrutinib新药上市申请及关键性研究数据

2018-10-26

bugit (审核中...)

前往app查看评论内容

#zanubrutinib#

CSCO 2018 | 第二代BTK抑制剂Zanubrutinib，持久和特异的靶向亲和力带来更优的疗效和安全性

2018-09-25

bugit (审核中...)

前往app查看评论内容

#zanubrutinib#

百济神州宣布中国药监局接受zanubrutinib用于治疗复发/难治性套细胞淋巴瘤的新药申请

2018-08-29

科室
- - 订阅+
  - 更多科室
工具
服务